I don’t think there is lack of interest for licensees in the DEP drugs. As I see it, the company has spent many millions (and many years!) on the trials and they are now awaiting/ expecting top line results of the monotherapies to be officially released in Q3 CY23. So why on earth would they announce license deals before then, having waited so long? These results will present a level playing field to all potential licensees of the drugs to make their bids.
At the present time, and with the company in silence mode, any valuations on HC can only be considered as speculation at best.
I don’t think there is lack of interest for licensees in the DEP...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.20M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $22.86K | 218.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 348003 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 54598 | 6 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
10.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 10.5¢ | 10.5¢ | 10.0¢ | 171817 | ||
| Last updated 15.35pm 05/06/2024 ? | |||||
| SPL (ASX) Chart |